Table 4.

Characteristics of IMID

IMID	Age	Sex, male n (%)	Family background	Usual treatment while UC in active phase	UC in active phase (%)	UC recovered (%)
Arthritis	56 (32–78)	7 (87.5)	Arthritis, Dermatomyositis	Tacrolimus 5 mg, Infliximab 5 mg/kg + Mesalazine 400 mg/day	87.5	50
Ankylosing spondylitis	54 (43–65)	2 (100)	None	Infliximab 5 mg/kg + Mesalazine 400 mg/day	50	0
Rheumatoid arthritis	75 (53–84)	1 (25)	None	Mesalazine 250 mg 3/day	100	0
Pyoderma gangrenosum	42 (30–57)	3 (75)	None	Mesalazine 250 mg/ 3day, Prednisolone 5 mg 2/day	75	50
Dermatitis	52 (43–60)	1 (16.7)	Arthritis	Azathioprine, Mesalazine	83.3	66.7
Primary sclerosing cholangitis	47 (32–68)	7 (100)	None	Mesalazine 400 mg	85.7	57.1

IMID: immune-mediated inflammatory diseases

UC: ulcerative colitis